Determination of Specificity and Sensitivity in Detecting Myocardial Infarction Using the EDE CARDIO BIO-MAP Machine (CARDIO BIO-MAP)
Determination of Specificity and Sensitivity in Detecting Myocardial Infarction Using the EDE CARDIO BIO-MAP Machine, the EDE CARDIO BIO-MAP Study
The goal of this observational study is to learn whether a non-invasive electromagnetic wave scanner (EDE CARDIO BIO-MAP) can help diagnose myocardial infarction (heart attack) in adults (18 years and older) who come to the emergency department with chest pain and suspected myocardial infarction. The main questions it aims to answer are:
- How sensitive and specific is the EDE scanner in diagnosing myocardial infarction (MI) compared with standard blood tests (e.g., cardiac troponin)?
- How sensitive and specific are the immediate blood measurements from a portable lab device compared with conventional hospital laboratory measurements? Researchers will compare the results of the EDE scanner and the portable lab with standard hospital blood test results and the final clinical diagnosis to see how accurately each detects MI.
Participants will:
- Have a research visit (30 minutes to 1 hour) during their emergency care, including a quick scan with the Exponential Deep Examination (EDE) device (attached to a phone or tablet) and a small research blood sample tested on a portable lab device
- Repeat the scan and blood sample 4 to 6 hours later, only if a second blood draw is already needed for their clinical care
- Answer questions about their medical and social history, and allow the study team to collect relevant results from their medical record Scanner results will not be shared with participants or used for their clinical care.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Myocardial infarction is a leading cause of death and disability worldwide. Current diagnosis relies on clinical assessment, electrocardiogram, and blood measurement of cardiac biomarkers such as troponin. Faster, non-invasive diagnostic tools could be especially valuable in the emergency setting, where timely intervention is critical.
The Exponential Deep Examination Cardio Bio-Map is a non-invasive device, classified as Class 1 under the European Conformity marking system, that analyzes passive electromagnetic signals (0.1 to 300 gigahertz) using artificial intelligence to measure cardiac biomarkers without a blood draw. Results are available within 50 milliseconds. The device does not collect or store patient data. It produces an immediate printed report, and all data processing occurs locally within Qatar. During the COVID-19 pandemic, the same technology detected the SARS-CoV-2 virus with a specificity of 95.62% and a sensitivity of 93.71% compared with polymerase chain reaction testing and antibody testing. This study will evaluate whether the device can screen for myocardial infarction through measurement of cardiac biomarkers, both in biological samples (in vitro, using a portable laboratory device) and directly in patients (in vivo, using the scanner).
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Charbel Abi Khalil, MD,PhD
- Número de teléfono: +974 4492 8484
- Correo electrónico: cha2022@qatar-med.cornell.edu
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Participants will be recruited at Hamad Medical Corporation
Descripción
Inclusion Criteria:
- Age ≥18 years.
- Adults presenting to the emergency room for acute chest pain.
- English or Arabic speakers.
Exclusion Criteria:
- Pregnancy (self-reported).
- Adults with cognitive disorders.
- Unconscious patients.
- Citizens from countries where the General Data Protection Regulation (GDPR) applies, due to regulatory constraints.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Sensitivity and specificity of the EDE CARDIO BIO-MAP scanner(in vivo) for detecting myocardial infarction
Periodo de tiempo: Baseline
|
Sensitivity (true positives / [true positives + false negatives]) and specificity (true negatives / [true negatives + false positives]) of the scanner in emergency room patients with suspected myocardial infarction, compared with standard hospital laboratory results (cardiac troponin, creatine kinase-myocardial band, myoglobin, B-type natriuretic peptide, N-terminal pro-B-type natriuretic peptide) and the final clinical diagnosis in the medical record. |
Baseline
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Sensitivity and specificity of the portable lab's immediate blood measurements (in vitro)
Periodo de tiempo: Baseline
|
Sensitivity and specificity of the portable lab's immediate blood measurements for myocardial infarction, compared with conventional hospital laboratory measurements, using a confusion matrix. |
Baseline
|
|
Accuracy of the EDE scanner
Periodo de tiempo: Baseline
|
Accuracy = (true positives + true negatives) / all results; |
Baseline
|
|
Misclassification rate of the EDE scanner
Periodo de tiempo: Baseline
|
Misclassification rate = (false positives + false negatives) / all results; |
Baseline
|
|
Precision of the EDE scanner
Periodo de tiempo: Baseline
|
precision = true positives / (true positives + false positives) |
Baseline
|
|
Accuracy of the portable lab
Periodo de tiempo: Baseline
|
Accuracy = (true positives + true negatives) / all results; |
Baseline
|
|
Misclassification rate of the portable lab
Periodo de tiempo: Baseline
|
Misclassification rate = (false positives + false negatives) / all results; |
Baseline
|
|
Precision of the portable lab
Periodo de tiempo: Baseline
|
precision = true positives / (true positives + false positives) |
Baseline
|
|
Correlation Between EDE Scanner and Portable Laboratory Values for Cardiac Biomarkers
Periodo de tiempo: Baseline
|
Pearson or Spearman correlation coefficient between scanner and portable lab values for cardiac biomarkers : Troponin T, Troponin I, Myoglobin, B-type Natriuretic Peptide, NT-proBNP, and Creatine Kinase-MB. |
Baseline
|
|
Predictive power of each cardiac biomarker for myocardial infarction
Periodo de tiempo: Baseline
|
Logistic regression, area under the receiver operating characteristic curve, and optimal diagnostic cutoffs for each cardiac biomarker: Troponin T, Troponin I, Myoglobin, B-type Natriuretic Peptide, NT-proBNP, and Creatine Kinase-MB. |
Baseline
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in cardiac biomarker levels between initial assessment and 4-6 hour follow-up
Periodo de tiempo: Baseline and 4-6 hours after initial assessment
|
Change in cardiac biomarker levels( Troponin T, Troponin I, Myoglobin, B-type Natriuretic Peptide, NT-proBNP, and Creatine Kinase-MB) between the initial assessment and the follow-up, in participants who have a second clinical blood draw. |
Baseline and 4-6 hours after initial assessment
|
|
Diagnostic performance of the scanner by sex
Periodo de tiempo: Baseline
|
Subgroup analysis of scanner sensitivity and specificity by sex |
Baseline
|
|
Diagnostic performance of the scanner by age group
Periodo de tiempo: Baseline
|
Subgroup analysis of scanner sensitivity and specificity by age group |
Baseline
|
|
Diagnostic performance of the scanner by symptom profile
Periodo de tiempo: Baseline
|
Subgroup analysis of scanner sensitivity and specificity by symptom profile. |
Baseline
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Charbel Abi Khalil, MD,PhD, Weill Cornell Medicine-Qatar
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 23-00017
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
ongoing discussion with the sponsor
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .